Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
Dominique Verhelle(Pfizer (United States)), Kyle Chan, Gregory D. Ferguson(Ferring Pharmaceuticals (United Kingdom)), Antonia Lopez‐Girona, Laure Moutouh–de Parseval, Kristen Jensen-Pergakes, Jessica H. Mueller, Peter Schäfer(Bristol-Myers Squibb (United States)), Roger Chen(UNSW Sydney), Laura G. Corral, Kevin Wong, Helen Brady, George W. Muller(University of Leeds), Emilia Glezer
Cited by 232
Related Papers
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
|Cancer Research|2015|275
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
|Journal of Clinical Investigation|2008|180